Anaphylactoid reactions associated with contaminated heparin from China;Les réactions anaphylactoïdes associées à l'héparine d'origine chinoise

Annales Pharmaceutiques Francaises

Volumn 69, Issue 5, 2011, Pages 258-264

  Montpas, N ^a   Desormeaux A ^a   Keire, D ^b   Adam, A ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Bradykinin; Des Arg9 bradykinin and anaphylactoid reactions; Heparin; Oversulfated chondroitin sulphate

Indexed keywords

BRADYKININ; CHONDROITIN SULFATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN;

ANAPHYLAXIS; ARTICLE; CHINA; DIALYSIS; DRUG CONTAMINATION; HEMODILUTION; HUMAN;

AMINOPEPTIDASES; ANAPHYLAXIS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; BRADYKININ; CHINA; CHONDROITIN SULFATES; DIALYSIS; DRUG CONTAMINATION; HEPARIN; HUMANS; KININS; SULFATES;

EID: 80052897700     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2011.06.007     Document Type: Article

References (33)

1. CDC. Acute allergic-type reactions among patients undergoing hemodialysis - multiple states, 2007-2008. MMWR Morb Mortal Wkly Rep 2008, 57:124-125.
2. Guerrini M., Beccati D., Shriver Z., Naggi A., Viswanathan K., Bisio A., et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008, 26:669-675.
3. Blossom D.B., Kallen A.J., Patel P.R., Elward A., Robinson L., Gao G., et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008, 359:2674-2684.
4. Adam A., Montpas N., Keire D., Desormeaux A., Brown N.J., Marceau F., et al. Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro. Biomaterials 2010, 31:5741-5748.
5. Capila I., Linhardt R.J. Heparin-protein interactions. Angew Chem Int Ed Engl 2002, 41:391-412.
6. McLean J. The thromboplastic action of cephalin. AJP 1916, 41:250-257.
7. Murray G.D., Best C.H. The use of heparin in thrombosis. Ann Surg 1938, 108:163-177.
8. Levieux D., Levieux A. Immunochemical control of the species origin of intestinal mucosa used for heparin purification. J Immunoassay Immunochem 2001, 22:127-145.
9. Laster J.L., Nichols W.K., Silver D. Thrombocytopenia associated with heparin-coated catheters in patients with heparin-associated antiplatelet antibodies. Arch Intern Med 1989, 149:2285-2287.
10. Cohen S.G., Zelaya-Quesada M. Portier, Richet, and the discovery of anaphylaxis: a centennial. J Allergy Clin Immunol 2002, 110:331-336.
11. Chatellier V. Bilan et perspectives pour les productions agricoles dans le contexte de la mondialisation et de la PAC. Association de Gestion et de Comptabilité, Agriculture, Artisanat et Commerce; 2009.
12. Levieux D. Sécurité sanitaire des héparines chinoises 2008, IDBiotech.
13. Beyer T., Matz M., Brinz D., Radler O., Wolf B., Norwig J., et al. Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market. Eur J Pharm Sci 2010, 40:297-304.
14. Chanard J. Anaphylaxis-like reactions in haemodialysis. Nephrol Ther 2008, 4:301-305.
15. Maruyama T., Toida T., Imanari T., Yu G., Linhardt R.J. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr Res 1998, 306:35-43.
16. Monneret C. Contaminated heparins. Ann Pharm Fr 2008, 66:212-215.
17. Greinacher A., Michels I., Schafer M., Kiefel V., Mueller-Eckhardt C. Heparin-associated thrombocytopenia in a patient treated with polysulphated chondroitin sulphate: evidence for immunological crossreactivity between heparin and polysulphated glycosaminoglycan. Br J Haematol 1992, 81:252-254.
18. Greinacher A., Warkentin T.E. Contaminated heparin. N Engl J Med 2008, 359:1291-1292.
19. FDA. Information on Heparin. US Food and Drug Administration, 2008. [cited 2011 april 13th] Available from: URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM112597.
20. Afssaps. Héparines: retour à la normale de l'approvisionnement. Agence française de sécurité sanitaire des produits de santé, 2008. [cited 2011 april 13th] Available from: URL: http://www.afssaps.fr/Infos-de-securite/Communiques-Points-presse/Heparines-retour-a-la-normale-de-l-approvisionnement.
21. (FDA). FDA Media Briefing on Heparin. US Food and Drug Administration 2008. [cited 2011 april 13th] Available from: URL: http://www.fda.gov/downloads/NewsEvents/Newsroom/MediaTranscripts/UCM169333.pdf.
22. (FDA). Warning Letter: Changzhou SPL Company, Ltd. US Food and Drug Administration, 2008. [cited 2011 april 13th] Available from: URL: http://www.fda.gov/./WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM054109.pdf.
23. Moreau M.E., Garbacki N., Molinaro G., Brown N.J., Marceau F., Adam A. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 2005, 99:6-38.
24. Cyr M., Lepage Y., Blais C., Gervais N., Cugno M., Rouleau J.L., et al. Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol 2001, 281:H275-H283.
25. Leeb-Lundberg L.M., Marceau F., Muller-Esterl W., Pettibone D.J., Zuraw B.L. International union of pharmacology XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005, 57:27-77.
26. Desormeaux A., Moreau M.E., Lepage Y., Chanard J., Adam A. The effect of electronegativity and angiotensin-converting enzyme inhibition on the kinin-forming capacity of polyacrylonitrile dialysis membranes. Biomaterials 2008, 29:1139-1146.
27. Blais C., Rouleau J.L., Brown N.J., Lepage Y., Spence D., Munoz C., et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999, 43:293-302.
28. Molinaro G., Duan Q.L., Chagnon M., Moreau M.E., Simon P., Clavel P., et al. Kinin-dependent hypersensitivity reactions in hemodialysis: metabolic and genetic factors. Kidney Int 2006, 70:1823-1831.
29. Kishimoto T.K., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008, 358:2457-2467.
30. Blais C., Marc-Aurele J., Simmons W.H., Loute G., Thibault P., Skidgel R.A., et al. Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. Peptides 1999, 20:421-430.
31. Decarie A., Adam A., Couture R. Effects of captopril and Icatibant on bradykinin (BK) and des [Arg9] BK in carrageenan-induced edema. Peptides 1996, 17:1009-1015.
32. Sabourin T., Guay K., Houle S., Bouthillier J., Bachvarov D.R., Adam A., et al. Absence of ligand-induced regulation of kinin receptor expression in the rabbit. Br J Pharmacol 2001, 133:1154-1162.
33. Villax G. Business of counterfeit heparin and its implications. European Fine Chemicals Group (EFCG) Pharma Business Conference. Lisbon, Portugal; 2008.